Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bemcentinib - BerGenBio/Rigel Pharmaceuticals

Drug Profile

Bemcentinib - BerGenBio/Rigel Pharmaceuticals

Alternative Names: BGB 324; BGB-3234; R-428

Latest Information Update: 12 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rigel Pharmaceuticals
  • Developer BerGenBio; Haukeland University Hospital; Merck Sharp & Dohme; Oslo University Hospital; University of Leicester; University of Texas Southwestern Medical Center
  • Class Antifibrotics; Antineoplastics; Antivirals; Benzocycloheptenes; Cycloheptanes; Hepatoprotectants; Pyridazines; Pyrrolidines; Small molecules; Triazoles
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III COVID 2019 infections
  • Phase II Acute myeloid leukaemia; Malignant melanoma; Malignant-mesothelioma; Myelodysplastic syndromes; Non-small cell lung cancer; Triple negative breast cancer
  • Phase I/II Glioblastoma; Pancreatic cancer
  • Preclinical Adult respiratory distress syndrome; Ebola virus infections; Influenza virus infections; Respiratory syncytial virus infections; Rhinovirus infections; Zika virus infection
  • No development reported Chronic myeloid leukaemia; Idiopathic pulmonary fibrosis; Non-alcoholic steatohepatitis; Solid tumours

Most Recent Events

  • 07 Feb 2024 Preclinical trials in Influenza virus infections in Norway (PO) before February 2024
  • 07 Feb 2024 Preclinical trials in Respiratory syncytial virus infections in Norway (PO) before February 2024
  • 07 Feb 2024 Preclinical trials in Rhinovirus infections in Norway (PO) before February 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top